Malignant Pleural Mesothelioma Market

The malignant pleural mesothelioma (MPM) market is expected to experience consistent growth throughout the forecast period (2025–2034). The anticipated launch of innovative therapies from companies such as AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, and others is projected to accelerate market expansion across the 7MM.

The malignant pleural mesothelioma market is anticipated to witness steady growth during the forecast timeframe (2025–2034). The introduction of novel treatment options by leading pharmaceutical and biotech companies, including AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, and others, is expected to significantly contribute to market growth across the 7MM.

DelveInsight’s Malignant Pleural Mesothelioma Market Insights report offers an in-depth analysis of current treatment paradigms, emerging malignant pleural mesothelioma therapies, individual drug market shares, and historical as well as forecasted malignant pleural mesothelioma market size from 2020 to 2034 across the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Malignant Pleural Mesothelioma Market Report

• According to DelveInsight’s analysis, the malignant pleural mesothelioma market size across the 7MM was estimated at USD 210 million in 2024.
• Among the currently available therapies, OPDIVO (Nivolumab) + YERVOY (Ipilimumab) dominated the market, generating approximately USD 140 million in revenue across the 7MM in 2024.
• In 2024, the total number of mesothelioma cases across the 7MM was estimated to be around 11,000, with a projected decline by 2034 at a CAGR of 0.3%.
• Several key players, including AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, Sellas Life Sciences Group, CRISPR Therapeutics AG, Vivace Therapeutics, NuCana plc, A2 Biotherapeutics, Tango Therapeutics, and others, are actively advancing innovative malignant pleural mesothelioma therapies. These emerging treatments are expected to enter the market during the forecast period and significantly reshape the competitive landscape.
• Notable malignant pleural mesothelioma pipeline therapies include Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, Thiostrepton (RSO-021), alinpepimut-S, CTX131, VT3888, NUC-3373 (Fosifloxuridine Nafalbenamide), A2B694, TNG462, among others.

Discover which therapies are expected to grab the malignant pleural mesothelioma market share @ Malignant Pleural Mesothelioma Market Report - https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Malignant Pleural Mesothelioma Overview

Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy originating from the mesothelial cells lining the pleura and is strongly linked to prolonged asbestos exposure. Characterized by rapid progression and poor prognosis, the disease predominantly affects older men several decades after initial exposure. Tumor heterogeneity contributes significantly to treatment resistance and complicates disease management.

To enhance diagnostic precision, the 2021 WHO Classification of Thoracic Tumors (IARC) updated disease terminology by replacing “diffuse malignant pleural mesothelioma” with “diffuse pleural mesothelioma” and “localized malignant pleural mesothelioma” with “localized pleural mesothelioma.”

Asbestos exposure remains the primary risk factor, causing chronic inflammation and cellular damage. Additional risk factors include exposure to erionite, prior radiation therapy, potential simian virus 40 involvement, genetic susceptibility—particularly BAP1 mutations—advanced age, and male gender.

Patients commonly present with symptoms such as chest pain and dyspnea due to pleural effusion or lung encasement. Systemic manifestations, including fatigue and weight loss, are often driven by cytokine-mediated processes. Some patients remain asymptomatic, emphasizing the importance of surveillance among high-risk populations.

Diagnosis relies on imaging modalities such as CT and PET scans, though histopathological confirmation remains the gold standard. Immunohistochemical markers assist in differentiating MPM from other malignancies, while biomarkers like mesothelin show potential but lack standalone diagnostic accuracy. Accurate staging, often involving invasive procedures, is critical for guiding treatment decisions and prognosis.